Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease

被引：24

作者：

Cabrera-Salazar, M. A. ^{[1
]}

Bercury, S. D. ^{[1
]}

Ziegler, R. J. ^{[1
]}

Marshall, J. ^{[1
]}

Hodges, B. L. ^{[1
]}

Chuang, W. -L. ^{[1
]}

Pacheco, J. ^{[1
]}

Li, L. ^{[1
]}

Cheng, S. H. ^{[1
]}

Scheule, R. K. ^{[1
]}

机构：

[1] Genzyme Corp, Framingham, MA 01701 USA

来源：

EXPERIMENTAL NEUROLOGY | 2010年 / 225卷 / 02期

关键词：

Neuronopathic Gaucher disease; Intracerebroventricular; Glucocerebrosidase; Glucosylceramide; Glucosylsphingosine; ENZYME REPLACEMENT THERAPY; GLUCOSYLSPHINGOSINE ACCUMULATION; TYPE-2; BRAIN; MICE; GLUCOSYLCERAMIDE; DEFICIENCY; INFANTILE; PHENOTYPE; BARRIER;

D O I：

10.1016/j.expneurol.2010.07.023

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Gaucher disease is caused by a deficit in the enzyme glucocerebrosidase. As a consequence, degradation of the glycolipids glucosylceramide (GluCer) and glucosylsphingosine (GluSph) is impaired, and their subsequent buildup can lead to significant pathology and early death. Type 1 Gaucher patients can be treated successfully with intravenous replacement enzyme, but this enzyme does not reach the CNS and thus does not ameliorate the neurological involvement in types 2 and 3 Gaucher disease. As one potential approach to treating these latter patients, we have evaluated intracerebroventricular (ICV) administration of recombinant human glucocerebrosidase (rhGC) in a mouse model of neuronopathic Gaucher disease. ICV administration resulted in enzyme distribution throughout the brain and alleviated neuropathology in multiple brain regions of this mouse model. Treatment also resulted in dose-dependent decreases in GluCer and GluSph and significantly extended survival. To evaluate the potential of continuous enzyme delivery, a group of animals was treated ICV with an adeno-associated viral vector encoding hGC and resulted in a further extension of survival. These data suggest that ICV administration of rhGC may represent a potential therapeutic approach for type 2/3 Gaucher patients. Preclinical evaluation in larger animals will be needed to ascertain the translatability of this approach to the clinic. (C) 2010 Elsevier Inc. All rights reserved.

引用

页码：436 / 444

页数：9

共 29 条

[1]

Barranger J., 1989, The Metabolic and Molecular Bases of Inherited Diseases, P1677

[2] PATHOLOGICAL FINDINGS IN GAUCHER DISEASE TYPE-2 PATIENTS FOLLOWING ENZYME THERAPY [J].